Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial

The ITACa trial was designed to define the role of cetuximab (Cet) and bevacizumab (Bev) in combination with standard chemotherapy (CT, FOLFIRI or FOLFOX4) as first- and second-line treatment in metastatic colorectal cancer. All patients with WT KRAS tumors who had been enrolled in the first-line tr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Passardi, Alessandro, Scarpi, Emanuela, Gelsomino, Fabio, Palladino, Maria Angela, Casadei Gardini, Andrea, Turci, Daniele, Chiuri, Vincenzo Emanuele, Mucciarini, Claudia, Tassinari, Davide, Ragazzini, Angela, Frassineti, Giovanni Luca, Valgiusti, Martina, Ulivi, Paola, Amadori, Dino
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5585399/
https://ncbi.nlm.nih.gov/pubmed/28874797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-11048-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados